WALTHAM, Mass., Feb. 22, 2022 /PRNewswire/ -- Ardelyx, Inc.
(Nasdaq: ARDX), a biopharmaceutical company founded with a mission
to discover, develop and commercialize innovative first-in-class
medicines that meet significant unmet medical needs, today
announced that it will hold a conference call on Monday February 28, at 4:30 pm Eastern Time to discuss fourth quarter
and year-end 2021 financial results and provide a corporate
update.
To participate in the conference call, please dial (855)
296-9612 (domestic) or (920) 663-6277 (international) and refer to
conference ID 2790368. Live audio of the conference call will be
simultaneously webcast and will be available under the Investors
section of the company's website at www.ardelyx.com. The
webcast will be archived and available for replay for 30 days
following the call.
About Ardelyx, Inc.
Ardelyx is focused on discovering, developing and
commercializing innovative first-in-class medicines to meet
significant unmet medical needs. Ardelyx received approval for
IBSRELA (tenapanor) with plans to launch in the second quarter of
2022. Ardelyx is developing tenapanor, a novel product candidate to
control serum phosphorus in adult patients with CKD on dialysis,
which has completed three successful Phase 3 trials. Ardelyx is
also advancing RDX013, a potassium secretagogue, for the potential
treatment of elevated serum potassium, or hyperkalemia, a problem
among certain patients with kidney and/or heart disease and has an
early-stage program in metabolic acidosis, a serious electrolyte
disorder in patients with CKD. Ardelyx has established
agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and
commercialization of tenapanor in their respective territories.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ardelyx-to-report-fourth-quarter-and-year-end-2021-financial-results-and-provide-corporate-update-on-february-28-2022-301487152.html
SOURCE Ardelyx